Campins Magda, Cossio Yolima, Martínez Xavier, Borruel Natalia
Rev Esp Enferm Dig. 2013 Feb;105(2):93-102. doi: 10.4321/s1130-01082013000200006.
Patients with inflammatory bowel disease (IBD) have a greater risk of infection associated with the endogenous immunosuppression brought about by their underlying disease as well as the exogenous immunosuppression resulting from their therapies. In the last few years guidelines and consensus papers have been issued on the indication of vaccines for these patients as primary prevention of infection. However, vaccine coverage is low, likely because the risk for infection and both safety and efficacy concerns regarding vaccines are scarcely perceived in such cases. The available scientific evidence shows that immunization is safe for most preparations, and bears no association with an increased risk for disease activity. This paper reviews the available scientific literature, and provides recommendations on the vaccination of adults with IBD.
炎症性肠病（IBD）患者由于基础疾病导致的内源性免疫抑制以及治疗引起的外源性免疫抑制，感染风险更高。在过去几年中，已发布了关于这些患者接种疫苗作为感染一级预防指征的指南和共识文件。然而，疫苗接种率较低，可能是因为在这种情况下，感染风险以及对疫苗安全性和有效性的担忧几乎未被察觉。现有的科学证据表明，大多数疫苗制剂的免疫接种是安全的，并且与疾病活动风险增加无关。本文回顾了现有的科学文献，并就IBD成年患者的疫苗接种提供建议。
